Neonatal outcome in alloimmune thrombocytopenia after maternal treatment with intravenous immunoglobulin

Blood Transfusion

Volumn 13, Issue 1, 2015, Pages 66-71

  Van Der Lugt, N Margreth ^a   Kamphuis, Marije M ^b   Paridaans, Noortje P M ^b   Figee, Anouk ^a   Oepkes, Dick ^b   Walther, Frans J ^a   Lopriore, Enrico ^a  

^a Willem Alexander Child and Youth Centre   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Alloimmune thrombocytopenia; Intracranial haemorrhage; Intravenous immunoglobulin; Neonatal

Indexed keywords

IMMUNOGLOBULIN; IMMUNOLOGIC FACTOR;

ARTICLE; BIRTH; BRAIN HEMORRHAGE; CLINICAL ARTICLE; GESTATIONAL AGE; HEMATOMA; HUMAN; NEONATAL ALLOIMMUNE THROMBOCYTOPENIA; NEWBORN; PETECHIA; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; CLINICAL TRIAL; FEMALE; MALE; MULTICENTER STUDY; PREGNANCY; THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE;

FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; INFANT, NEWBORN; MALE; PLATELET TRANSFUSION; PREGNANCY; THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE;

EID: 84922327034     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2014.0309-13     Document Type: Article

References (37)

1. Bussel JB, Zacharoulis S, Kramer K, et al. Clinical and diagnostic comparison of neonatal alloimmune thrombocytopenia to non-immune cases of thrombocytopenia. Pediatr Blood Cancer 2005;45:176-83.
2. Burrows RF, Kelton JG. Fetal thrombocytopenia and its relation to maternal thrombocytopenia. N Engl J Med 1993;329:1463-66.
3. Dreyfus M, Kaplan C, Verdy E, et al. Frequency of immune thrombocytopenia in newborns: a prospective study. Immune Thrombocytopenia Working Group. Blood 1997;89:4402-6.
4. Pearson HA, Shulman NR, Marder VJ, et al. Isoimmune neonatal thrombocytopenic purpura. Clinical and therapeutic considerations. Blood 1964;23:154-77.
5. Knight M, Pierce M, Allen D, et al. The incidence and outcomes of fetomaternal alloimmune thrombocytopenia: a UK national study using three data sources. Br J Haematol 2011;152:460-8.
6. Van Den Akker ES, Oepkes D, Lopriore E, et al. Noninvasive antenatal management of fetal and neonatal alloimmune thrombocytopenia: safe and effective. BJOG 2007;114:469-73.
7. Berkowitz RL, Kolb EA, McFarland JG, et al. Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia. Obstet Gynecol 2006;107:91-6.
8. Kamphuis MM, Paridaans N, Porcelijn L, et al. Screening in pregnancy for fetal or neonatal alloimmune thrombocytopenia: systematic review. BJOG 2010;117:1335-43.
9. Williamson LM, Hackett G, Rennie J, et al. The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PlA1, Zwa) as determined by antenatal screening. Blood 1998;92:2280-7.
10. Turner ML, Bessos H, Fagge T, et al. Prospective epidemiologic study of the outcome and cost-effectiveness of antenatal screening to detect neonatal alloimmune thrombocytopenia due to anti-HPA-1a. Transfusion 2005;45:1945-56.
11. Davoren A, McParland P, Crowley J, et al. Antenatal screening for human platelet antigen-1a: results of a prospective study at a large maternity hospital in Ireland. BJOG 2003;110:492-6.
12. Durand-Zaleski I, Schlegel N, Blum-Boisgard C, et al. Screening primiparous women and newborns for fetal/neonatal alloimmune thrombocytopenia: a prospective comparison of effectiveness and costs. Immune Thrombocytopenia Working Group. Am J Perinatol 1996;13:423-31.
13. Killie MK, Husebekk A, Kjeldsen-Kragh J, et al. A prospective study of maternal anti-HPA 1a antibody level as a potential predictor of alloimmune thrombocytopenia in the newborn. Haematologica 2008;93:870-7.
14. Tiller H, Killie MK, Skogen B, et al. Neonatal alloimmune thrombocytopenia in Norway: poor detection rate with nonscreening versus a general screening programme. BJOG 2009;116:594-8.
15. Mueller-Eckhardt C, Kiefel V, Grubert A, et al. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet 1989;1:363-6.
16. Bertrand G, Drame M, Martageix C, et al. Prediction of the fetal status in noninvasive management of alloimmune thrombocytopenia. Blood 2011;117:3209-13.
17. Bussel JB, Zabusky MR, Berkowitz RL, et al. Fetal alloimmune thrombocytopenia. N Engl J Med 1997;337:22-6.
18. Spencer JA, Burrows RF. Feto-maternal alloimmune thrombocytopenia: a literature review and statistical analysis. Aust N Z J Obstet Gynaecol 2001;41:45-55.
19. Tiller H, Kamphuis MM, Flodmark O, et al. Fetal intracranial haemorrhages caused by fetal and neonatal alloimmune thrombocytopenia: an observational cohort study of 43 cases from an international multicentre registry. BMJ Open 2013;3:e002490. DOI: 10.1136/bmjopen-2012-002490.
20. Berkowitz RL, Lesser ML, McFarland JG, et al. Antepartum treatment without early cordocentesis for standard-risk alloimmune thrombocytopenia: a randomized controlled trial. Obstet Gynecol 2007;110:249-55.
21. Bussel JB, Berkowitz RL, Hung C, et al. Intracranial hemorrhage in alloimmune thrombocytopenia: stratified management to prevent recurrence in the subsequent affected fetus. Am J Obstet Gynecol 2010;203:135.e1-14.
22. Rayment R, Brunskill SJ, Soothill PW, et al. Antenatal interventions for fetomaternal alloimmune thrombocytopenia. Cochrane Database Syst Rev 2011; CD004226.
23. Birchall JE, Murphy MF, Kaplan C, et al. European collaborative study of the antenatal management of fetomaternal alloimmune thrombocytopenia. Br J Haematol 2003;122:275-88.
24. Kamphuis MM, Oepkes D. Fetal and neonatal alloimmune thrombocytopenia: prenatal interventions. Prenat Diagn 2011;31:712-9.
25. Te Pas AB, Lopriore E, Van Den Akker ES, et al. Postnatal management of fetal and neonatal alloimmune thrombocytopenia: the role of matched platelet transfusion and IVIG. Eur J Pediatr 2007;166:1057-63.
26. Kiefel V, Bassler D, Kroll H, et al. Antigen-positive platelet transfusion in neonatal alloimmune thrombocytopenia (NAIT). Blood 2006;107:3761-3.
27. Allen D, Verjee S, Rees S, et al. Platelet transfusion in neonatal alloimmune thrombocytopenia. Blood 2007;109:388-389.
28. Bayley N. Bayley Scales of Infant and Toddler Development. 3rd ed. San Antonio: Pearson; 2009.
29. Mechoulan A, Kaplan C, Muller JY, et al. Fetal alloimmune thrombocytopenia: is less invasive antenatal management safe? J Matern Fetal Neonatal Med 2011;24:564-7.
30. Bussel JB, Berkowitz RL, Lynch L, et al. Antenatal management of alloimmune thrombocytopenia with intravenous gamma-globulin: a randomized trial of the addition of low-dose steroid to intravenous gamma-globulin. Am J Obstet Gynecol 1996;174:1414-23.
31. Radder CM, Brand A, Kanhai HH. Will it ever be possible to balance the risk of intracranial haemorrhage in fetal or neonatal alloimmune thrombocytopenia against the risk of treatment strategies to prevent it? Vo x Sang 2003;84:318-25.
32. Kaplan C, Morel-Kopp MC, Kroll H, et al. HPA-5b (Br (a)) neonatal alloimmune thrombocytopenia: clinical and immunological analysis of 39 cases. Br J Haematol 1991;78:425-9.
33. Yinon Y, Spira M, Solomon O, et al. Antenatal noninvasive treatment of patients at risk for alloimmune thrombocytopenia without a history of intracranial hemorrhage. Am J Obstet Gynecol 2006;195:1153-7.
34. Radder CM, Beekhuizen H, Kanhai HH, et al. Effect of maternal anti-HPA-1a antibodies and polyclonal IVIG on the activation status of vascular endothelial cells. Clin Exp Immunol 2004;137:216-22.
35. Van Den Akker ES, Oepkes D. Fetal and neonatal alloimmune thrombocytopenia. Best Pract Res Clin Obstet Gynaecol 2008;22:3-14.
36. Ni H, Chen P, Spring CM, et al. A novel murine model of fetal and neonatal alloimmune thrombocytopenia: response to intravenous IgG therapy. Blood 2006;107:2976-83.
37. Kjeldsen-Kragh J, Killie MK, Tomter G, et al. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia. Blood 2007;110:833-9.